Table 4. Best tumour response by RECIST criteria as a function of dacarbazine and dasatinib dose.
| Dacarbazine (mg m−2) | Dasatinib | Not evaluable | PD (%) | SD (%) | PR (%) | CR |
|---|---|---|---|---|---|---|
| 800 | 50 mg b.i.d. | — | 2/3 | 1/3 | — | — |
| 800 | 70 mg b.i.d. | 1 | 5/18 (27.8) | 11/18 (61.1) | 2/18 (11.1) | — |
| 1000 | 70 mg b.i.d. | 3 | 3/11 (27.3) | 6/11 (54.5) | 2/11 (18.2) | — |
| 1000 | 140 mg daily | — | 1/3 | 2/3 | — | — |
| 1000 | 100 mg daily | — | 5/11 (45.5) | 6/11 (54.5) | — | — |
Abbreviations: CR=complete response; PD=progressive disease; PR=partial response; RECIST=Response Evaluation Criteria in Solid Tumours; SD=stable disease.
Four patients were not evaluable for response due to adverse events before the first restaging scans.